|  Help  |  About  |  Contact Us

Publication : NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD.

First Author  Seimetz M Year  2020
Journal  Nat Metab Volume  2
Issue  6 Pages  532-546
PubMed ID  32694733 Mgi Jnum  J:347791
Mgi Id  MGI:7627200 Doi  10.1038/s42255-020-0215-8
Citation  Seimetz M, et al. (2020) NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nat Metab 2(6):532-546
abstractText  Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and death worldwide. Peroxynitrite, formed from nitric oxide, which is derived from inducible nitric oxide synthase, and superoxide, has been implicated in the development of emphysema, but the source of the superoxide was hitherto not characterized. Here, we identify the non-phagocytic NADPH oxidase organizer 1 (NOXO1) as the superoxide source and an essential driver of smoke-induced emphysema and pulmonary hypertension development in mice. NOXO1 is consistently upregulated in two models of lung emphysema, Cybb (also known as NADPH oxidase 2, Nox2)-knockout mice and wild-type mice with tobacco-smoke-induced emphysema, and in human COPD. Noxo1-knockout mice are protected against tobacco-smoke-induced pulmonary hypertension and emphysema. Quantification of superoxide, nitrotyrosine and multiple NOXO1-dependent signalling pathways confirm that peroxynitrite formation from nitric oxide and superoxide is a driver of lung emphysema. Our results suggest that NOXO1 may have potential as a therapeutic target in emphysema.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

10 Bio Entities

Trail: Publication

0 Expression